Tag: central nervous system
The functional sophistication of the spinal cord can have devastating consequences. Will modern scientific developments replicate its functions?
The “central nervous system” delicately orchestrates the complex concerto of our mental and physical faculties, from perception through to action and all the intermediary processes in-between. Such functional sophistication is disturbed in spinal cord injury, which can have devastating short-term and long-term consequences, determined by the level and severity of the injury.
Thousands of people worldwide suffer severe spinal cord injuries each year, but little is known about why these injuries often continue to deteriorate long after the initial damage occurs.
Yi Ren, a professor of biomedical sciences at the Florida State University College of Medicine, is making progress in understanding why such significant harm is inflicted in the weeks and months after a spinal injury. In a study published today in the journal Nature Neuroscience, Ren explained how a natural immune system response may contribute to additional injury.
Humans can regenerate their peripheral nerves (PNS), but the regenerative ability does not extend to the central nervous system (CNS). So, what changed? Previously, the focus had been on identifying the cellular and molecular contributors that differentiate this regenerative ability in CNS vs. PNS. But now there seems to be a shift towards recognizing the underlying genetic makeup differences between the two.
Researchers at Washington University School of Medicine in St. Louis have identified some of the critical steps taken by peripheral nerves – those in the arms and legs – as they regenerate.
Injection after an injury reduces inflammation and scarring
After a spinal cord injury, a significant amount of secondary nerve damage is caused by inflammation and internal scarring that inhibits the ability of the nervous system to repair itself.
A biodegradable nanoparticle injected after a spinal cord trauma prevented the inflammation and internal scarring that inhibits the repair process, reports a new Northwestern Medicine study.
A cell therapy intended to boost myelin regeneration — Q-Cells by Q Therapeutics — has received a green light from the U.S. Food and Drug Administration to proceed with a clinical trial in patients with transverse myelitis (TM), a disease that like multiple sclerosis is characterized by myelin damage.
FDA approval of the company’s Investigational New Drug (IND) application allows researchers to start a Phase 1/2 clinical trial in which nine patients will receive increasing doses of the treatment.
Researchers at ReNetX Bio are hoping a new name, the potential for a new influx of cash on the horizon and a new chief executive officer are the winning combination needed to bring its lead drug candidate to market.
ReNetX Bio is looking to guide its drug candidate, Nogo Trap, through its first round of clinical trials. Company officials say Nogo Trap is designed to help patients with chronic spinal cord injury.
Anna Hopson’s PowerPoint presentation and interactive online lesson about spinal cord injury. Anna covers everything related to spinal cord injuries in this 35 minute Microsoft Office Mix Presentation.
Monica A. Perez, P.T., Ph.D., Associate Professor, Department of Neurological Surgery and The Miami Project, and colleagues, recently published A novel cortical target to enhance hand motor output in humans with spinal cord injury in the June issue of Brain that provides the first evidence that cortical targets could represent a novel therapeutic site for improving motor function in humans paralyzed by spinal cord injury (SCI).
A main goal of rehabilitation strategies in humans with SCI is to strengthen transmission in spared neural networks. Although neuromodulatory strategies have targeted different sites within the central nervous system to restore motor function following SCI, the role of cortical targets remains poorly understood.
For a soldier who suffered a spinal cord injury on the battlefield, the promise of regenerative medicine is to fully repair the resulting limb paralysis. But that hope is still years from reality.
Not only powerful, but efficient. Studying diseases in lab-created tissue may help reduce the price tag — now roughly $1.8 billion — for bringing a new drug to market, which is one of the reasons Ashton received a National Science Foundation CAREER Award for advancing tissue engineering of the human spinal cord. During the project’s five-year funding period, his lab in the Wisconsin Institute for Discovery will fine-tune the technology for growing a neural tube, the developmental predecessor of the spinal cord, from scratch.
Findings by UCLA-led collaboration are an early step toward potential treatments for injuries to the central nervous system
Newswise — Whether or not nerve cells are able to regrow after injury depends on their location in the body. Injured nerve cells in the peripheral nervous system, such as those in the arms and legs, can recover and regrow, at least to some extent. But nerve cells in the central nervous system — the brain and spinal cord — can’t recover at all.